Smart Inhalers Market: Historical, Current and Projected Market Size, Competitive landscape & Forecast 2025

Smart Inhalers Market Share, Trends and Growth Analysis by Type (Dry Powder Inhaler and Metered Dose Inhaler), Application (Asthma, Chronic Obstructive Pulmonary Disease and others), End User (Hospitals & Clinics, Respiratory Care Centers and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025

Smart Inhalers are respiratory inhalers equipped with a digital sensor that tracks the data, such as the dosage timing, and monitors the use of the inhaler while scheduling the next dosage as well. It is a new-age digital technology designed to empower patients, care contributors, researchers, and physicians related to respiratory diseases through objective and accurate medication monitoring and reminders. Alerts for the daily dosage are generated via Bluetooth. 

According to Market Research Future (MRFR), the global Smart Inhaler Market is expected to reach USD 4725.69 MN by 2025. In its recently published research analysis, MRFR also asserts that the market would register a whopping CAGR of over 45% throughout the forecast period (2019-2025). Smart inhalers have been successfully improving patient outcomes while reducing the significant financial costs associated with suboptimal medication adherence. This makes smart inhalers the next big thing in the respiratory care segment. 

Increasing population becoming susceptible to indoor air pollutants worldwide and rise in the prevalence of asthma & COPD are key factors driving the smart inhalers market. Moreover, improved adherence rate driven by increasing patient’s preference to use digitalized medical devices for monitoring daily medication doses fosters the growth of the market.

Also, increased collaboration deeds between pharmaceutical companies and smart inhaler manufacturers to promote technological advancements are contributing to market growth. Increased focus on advancement in treatment methods, technological advancements led by R&D programs, online marketing strategies incorporated by key players in pharmaceutical and biotechnological industries are some of the major trends observed in the market.

On the other hand, high costs associated with the smart inhalers and COPD & asthma treatments, limited availability of smart inhalers, and misinterpretation of information are some of the major factors obstructing the growth of the market. Key pharmaceutical companies are adopting digital technology for improved disease management for asthma and COPD and for improved effectivity of medicines. Wide range of benefits, including reducing financial costs associated with suboptimal medication adherence to enhanced efficacy of medicines, makes smart inhalers most preferred and popular in the respiratory care segment.

Global Smart Inhalers Market – Segments

The report is segmented into four key market dynamics to widen the scope of understanding,

By Type : Dry Powder Inhaler and Metered-dose Inhaler.

By Application : Asthma and Chronic Obstructive Pulmonary Disease (COPD), among others.

By End-user : Hospitals & Clinics, Research Institute, and Respiratory Care Centers, among others.

By Regions : Asia Pacific,North America, Europe, and the Rest-of-the-World.

Browse Complete Report :

Global Smart Inhalers Market – Regional Analysis

North America leads the global smart inhalers market, accounting for the largest market share.  Increased awareness about asthma and COPD treatment and the increased adoption of smart inhalers help the region to cut the largest revenue share, globally. Moreover, large asthma and COPD patient population in the region foster the regional market growth.

The smart inhalers market in the European region took the second-largest position holding 31.89% market share, in 2018.  The presence of a number of noteworthy players such as Novartis, AstraZeneca, and Boehringer Ingelheim drive the regional market growth. Moreover, the high adoption of smart inhalers in hospitals and patients in European countries is expected to boost the growth in the regional market throughout the assessment period.

The Asia pacific smart inhalers market is emerging as a promising market, globally. Factors, such as the spreading awareness about the benefits that smart inhalers can provide in managing asthma and COPD, influence the market growth in the region. Besides, improvement in healthcare infrastructure with an increased budget for healthcare expenses would fuel the APAC smart inhalers market. The region is expected to grow rapidly throughout the forecast duration, with China being the major revenue contributor.

Global Smart Inhalers Market – Competitive Analysis

Highly competitive by nature, the smart inhalers market appears to be fragmented due to the presence of market titans in the market. To maintain their market positions. Key companies are venturing into new regions and countries with rapid expansion plans. Top players are substantially investing in R&D and clinical trials to accelerate product development and innovations and to cut down production costs.

Major Players:

Players leading the global smart inhalers market include AstraZeneca (UK), Adherium (New Zealand), Cohero Health (US), Gecko Health Innovations, Inc (US), GlaxoSmithKline (UK), Propeller Health (US), and Inspiro Medical (Israel), among others.

Industry/Innovation/ Related News:

March 29, 2019 --- Teva Pharmaceuticals (Israel), a leading pharma company, announced its plans to underpin its smart inhaler, clinical trial innovations through big data emphasis At MEDinIsrael conference 2019. At the event, the growing role of technology, big data, and analytics in the company was discussed alongside, the work the top Israeli pharma company has been doing in digital health.

The discussion included the company’s recently FDA-cleared smart inhaler ProAir Digihaler. Teva is planning to take the data from the smart inhaler about time, and number of inhalations, flow rate, volume to build an algorithm that can predict asthma exacerbation. The predicted exacerbation, about five or six days before it hits shows that it’s possible to prescribe some drugs and avoid the exacerbation.